Novartis sees single-digit growth with new CEO; J&J takes $13.6b charge in the wake of the new tax law; New York City invests in biotech
Drugmakers to remove incentives for sales reps marketing antibiotics; Mylan CEO defends EpiPen pricing; fitness trackers don't help people lose weight
Some U.S. hospitals still haven't received Valeant discounts; U.N. General Assembly will discuss antibiotic resistance; AstraZeneca diabetes drugs lowered blood sugar in study
England's NHS delays hep-C coverage due to pricing; Google reports 21% revenue growth; U.S. and U.K. announce partnership for antibiotic development
Hospitals struggle with high drug costs; the FDA approves new weight loss device; the ADA asks docs not to tweet, but they did anyway
The goal is to develop medications that move beyond the high-toxicity and low-efficacy profiles of older drugs.
The Medicines Company's commercial lead for infection disease care talks about its breakthrough antidote for carbapenem-resistant enterobacteriaceae.